Early technology assessment of new medical devices
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objectives: In the United States, medical devices represent an eighty-billion dollar a year market. The U.S. Food and Drug Administration rejects a significant number of applications of devices that reach the investigational stage. The prospects of improving patient condition, as well as firms' profits, are thus substantial, but fraught with uncertainties at the time when investments and design decisions are made. This study presents a quantitative model focused on the risk aspects of early technology assessment, designed to support the decisions of medical device firms in the investment and development stages. Methods: The model is based on the engineering risk analysis method involving systems analysis and probability. It assumes use of all evidence available (both direct and indirect) and integrates the information through a linear formula of aggregation of probability distributions. The model is illustrated by a schematic version of the case of the AtrialShaper, a device for the reduction of stroke risk that is currently in the preprototype stage. Results: The results of the modeling provide a more complete description of the evidence base available to support early-stage decisions, thus allowing comparison of alternative designs and management alternatives. Conclusions: The model presented here provides early-stage decision-support to industry, but also benefits regulators and payers in their later assessment of new devices and associated procedures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study
Benjamin, E. J., Wolf, P. A., D’Agostino, R. B., Silbershatz, H., Kannel, W. B., & Levy, D. (1998) · Circulation · doi:10.1161/01.cir.98.10.946 · Cited by 4,575
Cited by
IJzerman, M. J., Koffijberg, H., Fenwick, E., & Krahn, M. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0509-1 · Cited by 189
“According to Pietzsch and Paté-Cornell, early HTA is used to inform manufacturers and investors about the design and management of a technology, as well as regulatory and reimbursement strategy [12].”
BackgroundMethodInfluentialMEDICAL DEVICES EARLY ASSESSMENT METHODS: SYSTEMATIC LITERATURE REVIEW
Markiewicz, K., van Til, J. A., & IJzerman, M. J. (2014) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462314000026 · Cited by 87
“experts) [5]; Informal discussions [6]; Qualitative weighing of relevant factors [7]; Use cases writing [8]; Key informant interviews [9]; Strategic planning methods: PEST, SWOT [10]; Soft Systems Methodology [11]; Expert panels/elicitation [12]; Technology profiling (uncertainty profile and evidence profile) [13]; Wo…”
MethodLehoux, P., Miller, F. A., Daudelin, G., & Denis, J.-L. (2017) · International Journal of Health Policy and Management · doi:10.15171/ijhpm.2017.11 · Cited by 74
“International Journal of Health Policy and Management, 2017, 6(9), 509–518 511 investors, and regulatory agencies may influence the value proposition of a new technology, which refers to “the value created for users by the offering based on the technology.”
BackgroundInfluentialExploratory study of the state of environmentally conscious design in the medical device industry
Moultrie, J., Sutcliffe, L., & Maier, A. (2015) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2015.06.014 · Cited by 50
“Developing medical devices is complex, financially risky, requires large upfront investment and involves long lead times to market (Medina et al., 2013; Pietzsch and Pate-Cornell, 2008; Johnson and Moultrie, 2012).”
Background
Metadata
- Authors
- Pietzsch, J. B., & Paté-Cornell, M. E.
- Venue
- International Journal of Technology Assessment in Health Care
- Publisher
- Cambridge University Press (CUP)
- Published
- 2008-01
- Volume
- 24
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0266-4623 (ISSN-L)
- 1471-6348
- OpenAlex
- W2147713879
- Cited by
- 78
- References
- 1
- FWCI
- 15.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early technology assessment of new medical devices. https://app.cochat.ai/papers/10.1017/s0266462307080051
- The paper
- Pietzsch, J. B., & Paté-Cornell, M. E. (2008). Early technology assessment of new medical devices. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462307080051
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.